Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2016

01-06-2016 | Original Article

Relationship of body mass index with BRAF V600E mutation in papillary thyroid cancer

Authors: Rong-liang Shi, Ning Qu, Tian Liao, Wen-jun Wei, Zhong-wu Lu, Ben Ma, Yu-Long Wang, Qing-hai Ji

Published in: Tumor Biology | Issue 6/2016

Login to get access

Abstract

Current evidences suggest an influence of overweight body mass index (BMI) on the carcinogenesis in malignancies. However, the role of BMI is unclear in papillary thyroid cancer (PTC). The aim of the present study is to investigate the relationship between BMI and BRAF V600E mutation status in PTC. BRAF V600E mutation in 108 patients with PTC was analyzed by Sanger sequencing. The cutoff point of BMI was identified by X-tile for predicting mutation by overweight. Odds ratios (OR) and 95 % confidence interval (CI) of BRAF V600E mutation according to BMI and clinicopathologic variables were calculated using logistic regression models. Fifty-one patients were positive for BRAF V600E mutation. A positive relationship existed between BRAF V600E mutation and BMI (p = 0.039). A 24.3 kg/m2 was identified as cutoff point for differentiating greater than 52.0 % observed probability of mutation for BRAF V600E in entire cohort, which was similar to the midpoint between the upper limit of normal BMI and overweight defined by WHO (≥24 kg/m2). Multivariate analysis confirmed the association between BRAF V600E mutation with overweight BMI range (OR 7.645, 95 % CI 1.275–45.831, p = 0.026). This study suggests an influence of overweight BMI on the status of BRAF V600E in patients with PTC, whereas the underlying mechanism need to be further investigated.
Literature
1.
James FR, Wootton S, Jackson A, Wiseman M, Copson ER, Cutress RI. Obesity in breast cancer—what is the risk factor? Eur J Cancer. 2015;51:705–20.CrossRefPubMed
2.
Scarpa M, Ruffolo C, Erroi F, Fiorot A, Basato S, Pozza A, et al. Obesity is a risk factor for multifocal disease and recurrence after colorectal cancer surgery: a case–control study. Anticancer Res. 2014;34:5735–41.PubMed
3.
Ortiz-Mendoza CM, Velasco-Navarro C. [Obesity, a main risk factor for endometrial cancer]. Rev Med Inst Mex Seguro Soc. 2013;51:260–3.PubMed
4.
Han JM, Kim TY, Jeon MJ, Yim JH, Kim WG, Song DE, et al. Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. Eur J Endocrinol. 2013;168:879–86.CrossRefPubMed
5.
Anderson AS, Key TJ, Norat T, Scoccianti C, Cecchini M, Berrino F, et al. European code against cancer 4th edition: obesity, body fatness and cancer. Cancer Epidemiol. 2015;39 Suppl 1:S34–45.CrossRefPubMed
6.
Gathirua-Mwangi WG, Zollinger TW, Murage MJ, Pradhan KR, Champion VL. Adult BMI change and risk of breast cancer: national health and nutrition examination survey (NHANES) 2005–2010. Breast Cancer. 2015;22:648–56.CrossRefPubMedPubMedCentral
7.
Hursting SD, Nunez NP, Patel AC, Perkins SN, Lubet RA, Barrett JC. The utility of genetically altered mouse models for nutrition and cancer chemoprevention research. Mutat Res. 2005;576:80–92.CrossRefPubMed
8.
9.
Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373–9.CrossRefPubMed
10.
Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28:742–62.CrossRefPubMed
11.
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the ras/raf signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643–8.CrossRefPubMed
12.
Sobin LHGM, Wittekind CH, UICC. TNM classification of malignant tumors. 7th ed. New York: Wiley-Liss; 2009.
13.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMed
14.
Richter A, Grieu F, Carrello A, Amanuel B, Namdarian K, Rynska A, et al. A multisite blinded study for the detection of braf mutations in formalin-fixed, paraffin-embedded malignant melanoma. Sci Rep. 2013;3:1659.CrossRefPubMedPubMedCentral
15.
Campbell PT, Newton CC, Newcomb PA, Phipps AI, Ahnen DJ, Baron JA, Buchanan DD, Casey G, Cleary SP, Cotterchio M, Farris AB, Figueiredo JC, Gallinger S, Green RC, Haile RW, Hopper JL, Jenkins MA, Le Marchand L, Makar KW, McLaughlin JR, Potter JD, Renehan AG, Sinicrope FA, Thibodeau SN, Ulrich CM, Win AK, Lindor NM, Limburg PJ: Association between body mass index and mortality for colorectal cancer survivors: Overall and by tumor molecular phenotype. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2015.
16.
Brandstedt J, Wangefjord S, Nodin B, Eberhard J, Sundstrom M, Manjer J, et al. Associations of anthropometric factors with KRAS and BRAF mutation status of primary colorectal cancer in men and women: a cohort study. PLoS ONE. 2014;9, e98964.CrossRefPubMedPubMedCentral
17.
Hughes LA, Williamson EJ, van Engeland M, Jenkins MA, Giles GG, Hopper JL, et al. Body size and risk for colorectal cancers showing braf mutations or microsatellite instability: a pooled analysis. Int J Epidemiol. 2012;41:1060–72.CrossRefPubMed
18.
Kim B, Park SJ, Cheon JH, Kim TI, Kim WH, Hong SP. Clinical meaning of braf mutation in Korean patients with advanced colorectal cancer. World J Gastroenterol. 2014;20:4370–6.CrossRefPubMedPubMedCentral
19.
Slattery ML, Curtin K, Sweeney C, Levin TR, Potter J, Wolff RK, et al. Diet and lifestyle factor associations with cpg island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer. 2007;120:656–63.CrossRefPubMed
20.
Zhang W, Bai X, Ge H, Cui H, Wei Z, Han G. Meta-analysis in the association between obesity and risk of thyroid cancer. Int J Clin Exp Med. 2014;7:5268–74.PubMedPubMedCentral
21.
Hou P, Liu D, Xing M. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr Relat Cancer. 2011;18:687–97.CrossRefPubMedPubMedCentral
22.
Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015;33:42–50.CrossRefPubMed
23.
Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309:1493–501.CrossRefPubMedPubMedCentral
24.
25.
26.
Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009;94:1612–7.CrossRefPubMed
27.
Wang Y, Ji M, Wang W, Miao Z, Hou P, Chen X, et al. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Endocr Relat Cancer. 2008;15:183–90.CrossRefPubMed
28.
Guan H, Ji M, Hou P, Liu Z, Wang C, Shan Z, et al. Hypermethylation of the DNA mismatch repair gene hmlh1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer. 2008;113:247–55.CrossRefPubMed
29.
Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res. 2007;13:1341–9.CrossRefPubMed
30.
Eveleth PB, Andres R, Chumlea WC, Eiben O, Ge K, Harris T, et al. Uses and interpretation of anthropometry in the elderly for the assessment of physical status. Report to the nutrition unit of the world health organization: the expert subcommittee on the use and interpretation of anthropometry in the elderly. J Nutr Health Aging. 1998;2:5–17.PubMed
31.
Joensuu K, Hagstrom J, Leidenius M, Haglund C, Andersson LC, Sariola H, et al. Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases—elevated bmi-1 expression in late breast cancer relapses. Virchows Arch. 2011;459:31–9.CrossRefPubMed
32.
Faruk Aykan N, Yildiz I, Sen F, Kilic L, Keskin S, Ciftci R, et al. Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (MCRC) patients treated with bevacizumab-based therapy. Med Oncol. 2013;30:679.CrossRefPubMedPubMedCentral
33.
34.
Halnan KE. Influence of age and sex on incidence and prognosis of thyroid cancer. Three hundred forty-four cases followed for ten years. Cancer. 1966;19:1534–6.CrossRefPubMed
35.
Moreira Leite KR, de Araujo VC, Rezende Meirelles MI, Lopes Costa AD, Camara-Lopes LH. No relationship between proliferative activity and the macis prognostic scoring system in papillary thyroid carcinoma. Head Neck. 1999;21:602–5.CrossRefPubMed
36.
Rodriguez-Cuevas S, Labastida-Almendaro S, Cortes-Arroyo H, Lopez-Garza J, Barroso-Bravo S. Multifactorial analysis of survival and recurrences in differentiated thyroid cancer. Comparative evaluation of usefulness of ages, macis, and risk group scores in Mexican population. J Exp Clin Cancer Res. 2002;21:79–86.PubMed
37.
Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399–404.CrossRefPubMed
38.
Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, et al. The prevalence and prognostic value of braf mutation in thyroid cancer. Ann Surg. 2007;246:466–70. discussion 470–461.CrossRefPubMedPubMedCentral
39.
Hayes A, Gearon E, Backholer K, Bauman A, Peeters A. Age-specific changes in BMI and BMI distribution among Australian adults using cross-sectional surveys from 1980 to 2008. Int J Obes (Lond). 2015;39:1209–16.CrossRef
40.
Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005;65:4238–45.CrossRefPubMed
41.
Metadata
Title
Relationship of body mass index with BRAF V600E mutation in papillary thyroid cancer
Authors
Rong-liang Shi
Ning Qu
Tian Liao
Wen-jun Wei
Zhong-wu Lu
Ben Ma
Yu-Long Wang
Qing-hai Ji
Publication date
01-06-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4718-y

Other articles of this Issue 6/2016

Tumor Biology 6/2016 Go to the issue

Original Article

Reactive oxygen species mediate oxaliplatin-induced epithelial-mesenchymal transition and invasive potential in colon cancer

Original Article

Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development

Original Article

The tumor-to-breast volume ratio (TBR) predicts cancer-specific survival in breast cancer patients who underwent modified radical mastectomy

Original Article

Immunomodulatory potencies of isolated compounds from Crataegus azarolus through their antioxidant activities

Original Article

MicroRNA-520b affects the proliferation of human glioblastoma cells by directly targeting cyclin D1

Original Article

Sphingosine kinase 2 promotes colorectal cancer cell proliferation and invasion by enhancing MYC expression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits